Kornimate/medical-research-clean huggingface dataset:
intravascular ultrasound prediction of myocardial size and coronary computed tomography-derived ischemic burden for coronary lesion

Conditions: Coronary Artery Disease

Summary: the aims of this study are 1) to identify ivus determinants of the cams-derived myocardial territories subtended to the diseased vessels, 2) to find ivus determinant for the extent of cams-derived myocardial size, and 3) to develop the mathematical model that integrates the ivus information about myocardial territory and stenosis severity and predicts the extent of cams-derived myocardial size.


Eligibility criteria:
inclusion criteria: * age 20years or older * patients who have at least one epicardial coronary artery lesion (including isolated left main disease or side branch) with visually estimated diameter stenosis \>50% and take coronary angiography, ct angiography and ivus * willing and able to provide informed written consent exclusion criteria: * in-stent restenosis * bypass graft * suspected coronary spasm even after sufficient nitrate injected * cases in which the ivus imaging catheter failed to cross the lesion * poor quality ivus or ct images * visible collateral flow on angiography

Keywords: intravascular ultrasonography computed tomography
assessment of lung structure and function of infants born prematurely

Conditions: Premature Birth; Bronchopulmonary Dysplasia; Asthma

Summary: the purpose of this study is to evaluate the growth of the lung and how easily gas can be taken up by the lung in healthy infants born at full term without any breathing problems and infants born prematurely.

specific aim #1: determine the relationship between parenchymal tissue and alveolar volume with normal lung growth early in life. we hypothesize that during the first two years of life that parenchymal surface area and alveolar volume increase with somatic growth; however, the ratio of surface area to volume remains constant, while ventilation within the lung becomes more homogenous. specific aim #2: determine the pulmonary sequelae of premature birth and assess the effectiveness of early treatment strategies upon the pulmonary sequelae. we hypothesize that premature birth impedes growth and development of the lung parenchyma and the airways. in addition, initiating continuous positive airway pressure (cpap) and a permissive ventilatory strategy in very premature infants at birth will improve lung growth and lung function compared to treatment with early surfactant and conventional ventilation.

Eligibility criteria:
inclusion criteria: group 1: * 37 weeks or greater gestational age * age 2 to 36 months group 2: * 37 weeks or greater gestational age having a ct scan for non-respiratory issues. * age 2-36 months group 3: * 23-35 weeks gestational age exclusion criteria: group 1 and group 2: * congenital cardio-respiratory disease * hospitalization for respiratory illness * treatment with asthma medications * small for gestational age at birth group 3: * congenital cardio-respiratory disease * severe developmental delay

Keywords: infant, premature bronchopulmonary dysplasia asthma
a study of ascending single doses of surotomycin in healthy participants (mk-4261-008)

Conditions: Clostridium Difficile Associated Diarrhea (CDAD)

Summary: this study aims to assess the safety, tolerability, and pharmacokinetics (pk) of a single oral dose of surotomycin (cb-183,315) at ascending dose levels when given to healthy males and females.


Eligibility criteria:
inclusion criteria: * has no evidence of prior chronic gastrointestinal inflammatory disease such as inflammatory bowel disease or gastroesophageal reflux disease documented on endoscopy * electrocardiogram (ecg) shows no clinically significant abnormalities * is able to swallow capsules * is in good health exclusion criteria: * pregnant or lactating females * has had clostridium (c.) difficile disease within 1 year prior to entry into the study * has received an investigational drug or participated in any experimental procedure within1 month prior to study entry and at least 6 half lives from last intake of study drug * participants 18 to 49 years of age had taken any regular, prescribed, or over-the-counter medication * has any significant concurrent therapies * has a positive drug screen * has a positive human immunodeficiency virus (hiv), hepatitis b, or hepatitis c screen * has given more than 450 ml of blood (one unit) in the 60 days preceding screening * is an active intravenous drug user or abuses alcohol * has had a malignancy within the last 5 years * has inadequate protection against pregnancy during the conduct of the study and until 1 month after last dose of study drug * has received any antibiotics within 30 days prior to first dose of study drug * has been hospitalized within the past 30 days prior to study day 1 * has known hypersensitivity to daptomycin
coagulation disorders after aneurysmatic subarachnoid haemorrhage

Conditions: Aneurysmatic Subarachnoid Haemorrhage

Summary: the main purpose of this study is to analyse the on-going coagulation process after asah. for investigation the investigators use the rotational thromboelastometry (rotem) which is a point-of-care test using a variety of activators to provide a targeted and a dynamic analysis of coagulation cascade. this is a prospective, observational clinical study done in 16 asah patients treated in tampere university hospital intensive care unit and 16 control patients (elective craniotomy due to non-ruptured intracranial aneurysm.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * acute subarachnoid haemorrhage (confirmed by computed tomography, ct, or cerebrospinal fluid erythrocyte count over 1000 x 106/l) and confirmed origin either with computed angiography (cta) or digital subtraction angiography (dsa) * onset of symptoms ≤ 12 hours * expected to stay 72 hours in the icu exclusion criteria: * pregnancy * any long-term anticoagulant medication, except for low-dose aspirin (\<150 mg/day) * known active cancer
high-definition transcranial electrical stimulation for upper extremity rehabilitation

Conditions: Stroke

Summary: transcranial electrical stimulation (tces) is a non-invasive and safe treatment, which uses a low direct current or alternating current to change the excitability of the cerebral cortex. the tces has been applied in clinical trials related to rehabilitation research in recent years, and the safety and effectiveness have also been established. however,the existing tces products effect on the whole brain networks and lack special waveforms. therefore, we aim to develop a wearable tces with high definition and special waveforms in this study. this novel stimulation system will result in more precise and focal stimulation of selected brain regions with special waveforms to display better neuromodulation performance. we expect that the novel high-definition tces (hd-tces) combined with the upper extremity rehabilitation can shorten the duration of rehabilitative periods, improve stroke patients' activity of daily living, reduce the care burden of patients' family, and subsequently decrease the cost of health care insurance.


Eligibility criteria:
inclusion criteria: 1. age ≥ 20 years. 2. unilateral cerebral stroke with hemiplegia in brunnstrom stage iii-v. 3. 6 months to 5 years after stroke. 4. muscular inelasticity (spasticity) 1-3 on the affected upper limb, evaluated by the modified ashworth scale. exclusion criteria: 1. extremely sensitive to electrical stimulation and cannot tolerate it. 2. contracture on upper extremities, and limitation in joint range of motion. 3. the muscle tone was severe spasticity, 4. ossification or inflammation in muscle tissue. 5. a history of cardiopulmonary disease or arrhythmia. 6. with implantable medical electronic devices, like pacemaker. 7. pressure sores or wounds on the skin of head and upper extremities. 8. metal implants in the head (neck). 9. severe cognitive or psychiatric disorders, such as schizophrenia or dissociative identity disorder. 10. a history of seizure or other brain pathology. 11. brain surgery or severe brain trauma. 12. drug or alcohol abuse. 13. malignant neoplasm or rheumatism disorder, like sle, ra, or as.

Keywords: stroke, transcranial electrical stimulation, upper-limb rehabilitation
study of nifurtimox transfer into breastmilk in lactating women with chagas disease

Conditions: Chagas Disease; Lactation

Summary: the investigators propose to study the transfer of nifurtimox into breastmilk of lactating women who receive the drug for the treatment of chagas disease. breastmilk and blood samples will be obtained from these patients at pre-specified times after they take the clinically indicated medication, and the concentrations in both matrices will be compared to estimate degree of transfer. estimation of nifurtimox transfer into breastmilk will allow the evaluation of potential degree of exposure of infants breastfed by these women to nifurtimox. this study will help clarify safety of continuing breastfeeding while receiving treatment with nifurtimox for chagas disease.


Eligibility criteria:
inclusion criteria: * lactating women with chagas disease, not treated before * use of contraception exclusion criteria: * history of allergy to nifurtimox or its excipients * pregnancy * significant heart involvement (due to chagas disease) * significant systemic diseases that could affect the interpretation of the results in the opinion of the principal investigator

Keywords: chagas disease lactation breastmilk postpartum period infants pediatric clinical pharmacology developmental clinical pharmacology parasitology trypanosoma cruzi nifurtimox
a dose-escalation study of mdx-010 administered monthly as immunotherapy in subjects infected with human immunodeficiency virus (hiv)

Conditions: Human Immunodeficiency Virus (HIV)

Summary: the purpose of this study is to assess the safety and tolerability of 2 or 4 doses of mdx-010 in hiv-infected subjects


Eligibility criteria:
inclusion criteria: * detectable hiv viremia (hiv-1 rna level between 1,000 and 100,000 copies/ml) * cd4 count greater than or equal to 100 cells/mm3 * current antiretroviral therapy regimen following at least 2 previous changes for documented virologic failure * documented resistance tests demonstrating the presence of at least 1 mutation to each major therapeutic class of antiretroviral therapy * no significant organ compromise exclusion criteria: * initiation of any new medications that might reasonably affect the immune response or viral load within 4 weeks prior to screening * tetanus booster immunization within 2 months of screening, or a history of anaphylaxis or severe local reaction to the tetanus vaccine * history of autoimmune disease at risk for recurrence * current malignancy, except stage a or b cervical carcinoma or basal cell carcinoma * chronic viral hepatitis, due to hepatitis b or hepatitis c undergoing current treatment or hepatitis b dna greater than 25 pg/cc or hepatitis c rna greater than 20,000 iu/cc * currently undergoing treatment or prophylaxis for tuberculosis infection * chronic active infectious disease (other than hiv)
chest compression and sustained inflation

Conditions: Newborn Infants Having Asystole or Bradycardia at Birth

Summary: guidelines on neonatal resuscitation recommend 90 chest compressions (cc) and 30 manual inflations (3:1) per minute in newborns. the study aimed to determine if cc s during sustained inflations (si) improves recovery of asphyxiated newborns compared to coordinated 3:1 resuscitation.


Eligibility criteria:
inclusion criteria: newborn infants with asystole newborn infants with bradycardia exclusion criteria: -

Keywords: chest compression, delivery room, nicu,
daily living activities and exercise capacity in lipid storage diseases

Conditions: Lipid Storage Disease

Summary: lipid storage diseases (lsd) is a group of metabolic diseases that are manifested by exercise intolerance or muscle weakness, sometimes accompanied by systemic findings, which develop in some stages of muscle contraction due to necessary lipid transfer or destruction pathways. exercise intolerance in lsd can limit not only physical activity but also daily activities. in the literature, no study evaluated the activities of daily living in patients with lsd. the aim of this study was to investigate the effect of exercise capacity and daily living activities on the clinical features of lsd patients.

pulmonary functions are affected negatively in lipid storage diseases (lsd). it was shown that respiratory muscle strength and peak cough flow decreased in these cases. other respiratory system problems can be listed as; diaphragmatic dysfunction, hypoxemia, and hypercapnia. routine evaluation of respiratory function in lsd is recommended. a limited number of studies have shown that exercise tolerance is limited by the blockage of fat oxidation on the basis of muscle weakness and fatigue in lsd. although the assessment of exercise capacity is also an important indicator of heart-lung capacity monitoring, exercise capacity is not routinely measured in patients with lsd. exercise intolerance can limit not only physical activity but also daily activities. in the literature, the investigator's did not find any study evaluating the activities of daily living in patients with lsd. the aim of this study was to investigate the effect of exercise capacity and daily living activities on the clinical features of lsd patients.

Eligibility criteria:
inclusion criteria: * being diagnosed with lipid storage disease clinically and histopathologically. exclusion criteria: * severe pulmonary parenchymal disease, * cardiac problems * renal or hepatic dysfunction * uncontrolled hypothyroidism * acute infection * malignancy

Keywords: exercise capacity activities of daily living
stress and marijuana cue-elicited craving and reactivity

Conditions: Cannabis Use Disorders

Summary: the purpose of this study is to explore the interaction between stress and marijuana cues, in hopes that it may lead to the development of new treatments for marijuana dependence.

although use of marijuana is widespread, little research has focused on the treatment of marijuana use disorders or on predictors of relapse. although several factors contributing to relapse have been explored in other dependencies (i.e., alcohol, cocaine), little research has focused on drug cue-related or stress-induced relapse in marijuana-dependent individuals. cue reactivity is a construct measured in a laboratory procedure where an individual's subjective, behavioral, and physiological responses are assessed following exposure to drug-related environmental cues or stressors. investigating the effects of drug-related environmental cues and stress in marijuana-dependent individuals will be useful in guiding treatment development.

Eligibility criteria:
inclusion criteria: * meets diagnostic and statistical methods (dsm)-iv criteria for marijuana dependence * between the ages of 18 and 65 * must abstain from marijuana use the day of testing and other drug use three days prior to testing exclusion criteria: * must not be taking any psychoactive medication, or medication that alters the hypothalamic pituitary adrenal (hpa) axis functioning * must not be taking any medications that alter heart rate or skin conductance monitoring * cannot meet criteria for current major axis i disorder (may alter response to stress) * cannot be morbidly obese (body mass index \>39) * cannot meet current abuse or dependence criteria of other substances in past 90 days * must not have a medical condition that impacts hpa functioning (hypertension, chronic pain, addison's disease)

Keywords: substance-related disorders
sacral nerve stimulation for anal incontinence and bowel control

Conditions: Fecal Incontinence and Constipation

Summary: multicenter european study to evaluate efficacy and safety of sacral nerve stimulation with interstim therapy to treat fecal incontinence or constipation


Eligibility criteria:
140 patients (7 study groups, up to 20 implanted patients per study group) fecal incontinence groups: main inclusion criteria: * fecal incontinence (defined as incontinence to solid or liquid stool \> 1 / week); * failed biofeedback or medical therapy; groups 1 - 5 patients with: * group 1) circumferentially intact external anal sphincter, no previous surgery; * group 2) circumferentially intact external anal sphincter after surgical repair; * group 3) rectal prolapse repaired with a rectopexy; * group 4) spinal injury including disc prolapse; * group 5) sigmoid or partial rectal resection with colorectal or coloanal anastomosis constipation groups: main inclusion criteria: * chronic constipation (defined as \ 25% of bowel movements required straining; and/or \>25% of bowel movements patient did not feel empty afterwards) with symptoms more than 1 year * failed biofeedback or medical therapy; groups 6 - 7 patients with: * group 6) idiopathic slow transit constipation as proven on colonic transit studies; * group 7) normal colonic transit studies but chronic constipation due to either pelvic floor dysfunction or disordered defecation.

Keywords: slow transit constipation fecal incontinence constipation idiopathic slow transit constipation chronic constipation
safety and effectiveness of genoss des in patients with multivessel coronary artery disease

Conditions: Percutaneous Coronary Intervention; Multivessel Coronary Artery Disease

Summary: the investigators intend to establish a multicenter prospective observational study by enrolling and tracking patients with multivessel coronary artery disease (mvcad) using genoss des, a device manufactured with pure domestic technology. the study aims to evaluate the efficacy and safety of genoss des in mvcad patients.

this study is a sponsor-driven clinical trial (sit) that aims to enroll patients who have undergone treatment for multivessel coronary artery disease using genoss stents. the study involves collecting data on the clinical and surgical processes of patients and tracking the occurrence of clinical events. this prospective, multicenter observational study registers patients with acute coronary artery disease who have been treated with genoss stents at a total of 8 institutions. as it is an observational study, the number of subjects is not separately calculated, but the plan is to recruit a total of 1,000 participants during the study registration period.

Eligibility criteria:
inclusion criteria: * adults aged 19 years and older * individuals with multivessel coronary artery disiease(mvcad), including those with recurrent lesions at the procedure site, such as neo-atherosclerotic lesions. * participants who have undergone percutanoeus coronary intervention (pci) with genoss stnets * participants who have agreed to the trial protocol and clinical follow-up plan, have voluntarily decided to participate in this clinical trial, and have provided written consent in the informed consent form for trial participation. (note: foreign participants must be fluent in korean and capable of understanding korean documents, including the informed consent form, to be included. exclusion criteria: * trial participants with known hypersensitivity or contraindications to the following drugs or substances: heparin, aspirin, clopidogrel, cilostazol, contrast agents (note: even participants with hypersensitivity to contrast agents may be eligible for enrollment if their sensitivity can be controlled by steroids and antihistamines; however, those with known anaphylaxis are excluded). * cases where balloon expansion is unsuccessful during balloon angioplasty at the stenotic site. * participants with an expected residual lifespan of less than one year. * those who are planning to become pregnant, pregnant, or breastfeeding. * participants who presented with cardiogenic shock during hospitalization and are predicted to have a low likelihood of survival based on medical judgment. * individuals deemed unsuitable for this clinical trial or those for whom participation may increase risks related to trial involvement, as determined by the investigator. * foreign participants who cannot fluently speak korean and have difficulty understanding korean documents.
high intensity interval training and hypoxic conditioning in obese patients

Conditions: Obesity

Summary: the present study aims at evaluating the effect of two innovative treatment strategies in obese patients: high intensity interval training and hypoxic conditioning. obese patients will be randomized in groups performing high intensity interval training, constant load training, hypoxic conditioning or placebo normoxic conditioning for 8 weeks. the effects of the interventions will be measured regarding exercise tolerance, blood pressure, body composition, metabolic status.

120 obese patients will be randomized to 6 intervention groups. each group will follow an 8-week intervention (3 session per week) with either high intensity interval training in normoxia or hypoxia, constant load exercise training in normoxia or hypoxia, hypoxic or normoxic (placebo) conditioning at rest. exercise capacity, metabolic status, blood pressure, vascular function and physical activity will be assessed before and after the intervention.

Eligibility criteria:
inclusion criteria: * bmi between 27 and 35 kg/m² * physical activity \<2 hours/week * no chronic disease or treatment able to interfere with inflammation and metabolic perturbatiosn associated with obesity exclusion criteria: * diabetes mellitus treated with insulin * auto-immune or inflammatory diseases requiring long term therapy * unstable dysthyroidism * bariatric surgery within the past 18 months * tumoral, inflammatory, infectious, cardiac, respiratory, kidney, digestive disease * untreated sleep apnea
multi-marker approach for risk assessment in pah

Conditions: Pulmonary Arterial Hypertension

Summary: prospective registry including incident patients and prevalent patients which pretends to identify clinical characteristics, treatment trends in-hospital and ten years follow-up outcome through major adverse cardiovascular events (mace) in a china population with well characterized pah.

baseline include: an echocardiogram to assess the size, shape, pumping action and the extent of any damage to the heart. lung function tests which include blowing measurements to assess gas volumes within the lungs as well as assessment of how the lungs exchange gases. right heart catheterisation (rhc) to diagnose pah optional cardiac magnetic resonance tests. 6 minute walk distance (6mwd). to measure exercise capacity electrocardiogram (ecg), a test that measures the electrical activity of the heart blood tests mace include: death heart/lung transplantation atrial septostomy hospitalization due to worsening of pah start of new specific pah treatment persistent decrease of \>15% from baseline in 6mwd (or \>30% compared with last study-related measurement) persistent worsening of world health organization (who) functional class (fc）

Eligibility criteria:
inclusion criteria: diagnosis of pah (by rhc) exclusion criteria: refusal to participate.
evaluation of efficacy and safety of a single dose of exa-cel in participants with severe sickle cell disease, βs/βc genotype

Conditions: Sickle Cell Disease

Summary: the purpose of the study is to evaluate the efficacy and safety of ctx001 (exa-cel) in adolescent and adult participants with severe sickle cell disease (scd), βs/βc genotype (hbsc).


Eligibility criteria:
key inclusion criteria: * participants with documented βs/βc (hbsc) genotype * participants must be eligible for autologous stem cell transplant as per investigator's judgment key exclusion criteria: * a willing and healthy 10/10 human leukocyte antigen (hla)-matched related donor is available per investigator's judgement * participants with prior hematopoietic stem cell transplant (hsct) * treatment with regular rbc transfusions that, in the opinion of the investigator, cannot be interrupted after engraftment. other protocol defined inclusion/exclusion criteria may apply.